The February 2019 meeting of the Pharmacology and Therapeutics Advisory Committee (PTAC) included review of the November 2018 Rare Disorders Subcommittee meeting recommendations to fund 4 new Medicines. During its meeting PTAC accepted the high priority recommendations to fund two Te Arai BioFarma products – Carglumic acid (for the treatment of metabolic disorders CPS1 and NAGs) […]
Read MoreThe PHARMAC Rare Disorders Subcommittee met November 5 and 6 2018 to consider the funding of Medicines for the treatment of Rare Disorders. Rare Disorders are defined as those affecting less than 1 in 50,000 New Zealanders, often these Medicines are referred to a Orphan Medicines. The subcommittee can recommend a Medicine is funded, decline […]
Read MoreThe Medicine sapropterin has been recommended to be funded by PHARMACs Pharmacology and Therapeutics Advisory Committee (PTAC). Sapropterin is a treatment for a rare metabolic condition phenylketonuria (PKU), which is one of the disorders screened for at birth. PKU results in an inability for the body to process the amino acid phenylalanine causing accumulation. Phenylalanine is […]
Read More
The Te Arai BioFarma pharmaceutical product sapropterin has been registered by Medsafe for supply to New Zealanders. Registration occurred during international PKU awareness month. Sapropterin has been designated as an orphan drug for treating the rare metabolic condition phenylketonuria (PKU). PKU leads to an abnormally high concentration of the amino acid phenylalanine (Phe) in […]
Read More
The pharmaceutical buying agency PHARMAC has received a positive recommendation to fund Trinomia, a combination of aspirin (a blood ‘thinning’ agent to reduce blood clots), atorvastin (to reduce harmful cholesterol levels) and ramipril (to reduce blood pressure) for New Zealanders. PHARMACs cardiovascular subcommittee, mainly specialist cardiologists, provides clinical advice for PHARMAC. The committee has recommended […]
Read More
A new evidence review for the prevention of infection and wound management have recently been released. The review is accompanied by training modules supported by The Accident Compensation Corporation (ACC). The relatively high incidence of wound infection in New Zealand coupled with reduced health outcomes have prompted its release. Microdacyn Wound Care Solution and Hydrogel […]
Read More
New Zealand research has demonstrated that a cardiovascular polypill can improve adherence to medicines proven to improve survival. Medicines are only effective if we take them although in New Zealand only a fraction of people that have suffered a cardiovascular event (heart attack or stroke) take the medicines proven to make them live longer. This […]
Read More
Trinomia®,the first cardiovascular polypill, is being considered by the WHO as an Essential Medicine. Inclusion on the Essential Medicines List (EML) allow access and funding for poor, lower and middle income countries. Supporters of the application including institutes such as Oxford University, the University of Auckland, Harvard Medical School and the World Heart Federation […]
Read More
Microdacyn wound care solution has been included in the new International Wound Infection Institute (IWII) clinical practice Guidelines. The IWII is a multidisciplinary international group of experts dedicated to sharing the latest developments in wound infection and infection prevention. The guidelines have a focus on biofilm and wound infection. Microdacyn is newly included […]
Read More
UroFem 1000mg d-mannose tablets are now a listed medical consumable, meaning UroFem is funded for relevant people eligible under Accident Compensation Corporation (ACC). Urinary Tract Infections (UTIs) affect a large number of people that have received an accident related injury, including trauma and burns. People most affected include those with a spinal cord injury […]
Read More
PO Box 46205,
Herne Bay 1147,
Auckland, New Zealand
0800 832 724